Anti-retroviral therapy has transformed HIV-1 infection into a managed condition with near normal life expectancy. However, a significant number of patients remain with limited therapeutic options due to HIV-1 resistance, side effects or drug costs. Further, it is likely that current drugs will not retain efficacy, due to risks of side-effects and transmitted resistance. We describe compound 5660386 (3-ethyl-2-[3-(1,3,3-trimethyl-1,3-dihydro-2H-indol-2-ylidene)-1-propen-1- yl]-1,3-benzothiazol-3-ium) as a novel inhibitor of HIV-1 entry. Compound 5660386 inhibits HIV-1 entry in cell lines and primary cells, binds to HIV-1 envelope protein and inhibits the interaction of GP120 to CD4. Further, compound 5660386 showed a unique and broad range activity against primary HIV-1 isolates from different subtypes and geographical areas. Development of small molecule entry inhibitors of HIV-1 such as 5660386 may lead to novel classes of anti-HIV-1 therapeutics. These inhibitors may be particularly effective against viruses resistant to current anti-retroviral drugs and could have potential applications in both treatment and prevention.